Novel immunotherapy combinations for genitourinary cancers
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial Carcinoma /von 2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-262New treatment modalities with vaccine therapy in renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2019-04-01 / Urol Ann 2019 Apr-Jun;11(2):119-125Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial Carcinoma /von 2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-277Current status of clinical trials assessing oncolytic virus therapy for urological cancers
/in Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial Carcinoma /von 2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2017-03-01 / Immunotherapy 2017 03;9(4):319-329Recent advances in immuno-oncology and its application to urological cancers
/in Dendritic Cells, Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial Carcinoma /von 2016-06-03 / BJU Int. 2016 10;118(4):506-14Human renal carcinoma cells respond to Newcastle disease virus infection through activation of the p38 MAPK/NF-κB/IκBα pathway
/in Hypernephroma, International Publications, Newcastle Disease Virus /von 2015-05-01 / Cell Oncol (Dordr) 2015 Aug;38(4):279-88Matched-pair analysis of dendritic cell versus targeted-therapy in patients with metastatic renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International Publications /von 2015-03-01 / Anticancer Res. 2015 Mar;35(3):1575-82Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
/in Dendritic Cells, Hypernephroma, International Publications, Malignant Melanoma /von 2014-09-23 / J Transl Med 2014 Sep;12:262
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de